Charles
River Laboratories International, Inc. (NYSE: CRL) today announced
that its team of leading Central Nervous System (CNS) researchers is
presenting 25 posters at Neuroscience
2015, the annual meeting of the Society
for Neuroscience (SfN). The meeting, which has a lengthy history of
scientific engagement and excellence, is taking place this week at
McCormick Place in Chicago, Illinois.
“This is an exciting time for neuroscience research and we are pleased
to be at the forefront,” said Patrick Sweeney, Managing Director of
Charles River Discovery Services. “This year, we have partnered with
several clients to present our latest research findings and are hosting
two scientific events that will address the current thinking in the
areas of orphan drug development and disorders associated with protein
misfolding. Neuroscience 2015 offers our experts the opportunity to
collaborate with top scientists from across the globe as we work to
advance research in this rapidly transforming field.”
Among the posters the Charles River team will present are tools,
applications, and assays for research targeting Huntington’s,
Alzheimer’s, Parkinson’s, Multiple Sclerosis, Autism, Depression and
other neurological disorders. Noteworthy examples include:
-
A collaboration profiling efforts towards the development of a PET
tracer for aggregated α-synuclein, which is thought to play a role in
the pathology of Parkinson’s disease. (Studies Towards the
Development of a PET Tracer for Aggregated α-Synuclein)
-
A collaboration to establish optimal parameters for the use of BOLD
contrast-based phMRI as a tool in CNS disease research. (Blood
Oxygenation Level-Dependent (BOLD) Contrast-Based Pharmacological MRI)
-
Behavioral characterization of a genetically modified model for use in
development of therapies targeting autism spectrum disorder. (Characterization
of BTBR T+tf/J Model for Autism Spectrum Disorder)
-
A collaboration to assess the chronic social defeat assay for
alterations in an enzyme thought to contribute to depressive symptoms
in humans, and the response to its inhibition. (Chronic Social
Defeat Assay for Assessing Anti-Depression Therapies)
A full schedule of Charles River’s poster presentations is available to download,
and reprints of each poster are available in Charles River’s booth
(#1415) during the conference. Additionally, CNS experts are available
for meetings with those interested in discussing neuroscience research.
Throughout the conference, Charles River will be providing live updates
on the Eureka
Blog, including reviews of scientific sessions and input on the
research being presented.
To learn more about Charles River’s presence at SfN’s Neuroscience 2015,
please visit our website.
About the Society for Neuroscience
The Society
for Neuroscience is the world’s largest organization of scientists
and physicians devoted to understanding the brain and nervous system.
The nonprofit organization, founded in 1969, now has nearly 40,000
members in more than 90 countries and 130 chapters worldwide.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151019005196/en/
Copyright Business Wire 2015